Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00509665 · OUTCOME

Progression-free Survival

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer · Source last updated 2018-07-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Through the end of follow up, for an average of 8 months

Analysis population: Only patients who had re-staging scans are included in the number of participants analyzed.

Groups in this outcome

Gemcitabine+Doxorubicin

doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gemcitabine+Doxorubicin17

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Gemcitabine+Doxorubicin1.6Not reported1.44.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.4
        upper Limit
        4.2
        value
        1.6
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
    id
    OG000
    title
    Gemcitabine+Doxorubicin
param Type
MEDIAN
population Description
Only patients who had re-staging scans are included in the number of participants analyzed.
reporting Status
POSTED
time Frame
Through the end of follow up, for an average of 8 months
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice